Indicaciones y contraindicaciones oncológicas del uso de hormonas en la menopausia
DOI:
https://doi.org/10.31053/1853.0605.v62.n2.27917Palavras-chave:
.Resumo
Las expectativas de vida han cambiado ci manejo de la menopausia, etapa de la vida en la que la mujer presenta la mayor incidencia de cáncer. La terapia hormonal (TH) tiene en la actualidad indicaciones más acotadas y en particular en las pacientes que ya tuvieron cáncer. Las contraindicaciones oncológicas para el uso de TH son analizadas en relación a tumores hormono dependientes (endometrio y mama), a los con dependencia parcial (ovario y adenocarcinoma de cuello) y a los independientes (cuello,vulva y vagina).El cáncer colorectal, de alta mortalidad, se suponía protegido por TH, pero hoy no se puede confirmar esa observación. El aumento de incidencia y mortalidad del cáncer de maina es concluyente. La alta prevalencia de este tumor invita a ser cautelosos y advertidos en el diagnostico precoz en aquellas poblaciones mas expuestas. La TH combinada y por periodos de mas de 10 años demostró un incipiente incremento. Se esta en la búsqueda de hormonas selectivas que no estimulen los receptores en la mamay en el enclometrio y que actúen favorablemente sobre otras áreas.
Downloads
Referências
Pickard JH,Yeh I,Weeler JE et al Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone Fertility and Sterility 2001,76:25
Scarabin PY,Oger E, Plu-Bureau G D Differential association of oral and transdermal estrogen replacement therapy with venous thromboembolism risk Lancet 2003,362:428
Pike MC,Peters RK,Cozen W,et al Estrogen-progestin replacement therapy and endometrial cancer.J Nati Cancer Inst. 1997,89:1110
Giordano S,diRienzo MF,Olivero M,et al The c-metIHGF receptor in human tumor European J Cancer Prev. 1992,1(suppl) 45:9
Marconcini L,Marchio S, Morbidelli L, et al C-fos induced growth factor/ vascular endotelial factor D induces angiogenesis. Proc. Natl Acad. Sci USA 1999,96:9671
McCawley LJ,Matrisian LM Matriz metal lo - pro te i nasa mu it i funcional contributor to tumor progresión. Mol.Med Today 2000,6:149
Morin MJ,From oncogene todrug:develoment of small molecule tyrosine kinase inhibitors as antitumor and antiangiogenesis agents. Oncog. 2000, 19:6574
Oreen PK,Weiss NS, McKnight B et al Risk of endometrial cancer following cessation of menopausal hormone use.Cancer Cause Control 1996,7:575
Sturdee DW,Ulrch LG, Barlow DH, et al The endometrial response to sequential and continuous combined estrogen progestogen replacement therapy. Br J Obstet Gynaecol. 2000,107:1392
Wells M, Ulrich LO, Sturdee DW, et al Effect on endometrium of long term treatment with continuous combined estrogen-progestogen replacement therapy Br J. Br. Med, Journal 2002.325:239
Anderson GL, Judd HL, KaunitzAM, et al Effects of estrogen plus progestin on gynaecologic cancers and associated diagnosis procedures.JAMA 2003,290:1739
Hempling Wong C,Piver MS et al Hormone replacement therapy as a risk factor for epithelial ovarian cancer:results of a case control study. Obstet,Gyn 1997,89:1012
Garg RKerlikwski K,Subak L,et al Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a metanalysis. Obstet.Gynecol 1998,92:472
Riman T,Dickman RNilsson S, et al Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J. Natl. C. Inst 2002, 94:497
Roussow JE,Andersson GL,Prentice RL,et al Risk and benefits of estrogen plus progestin in healthy posmenopausal women.JAMA 2002,288:321
Lacey JV,Mink P,Lubin JH,et al Menopausal hormone replacement therapy and risk of ovarian cancer JAMA 2002,288:334
Rodríguez C,Patel AV,Calle EE, et al Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women JAMA2001,285: 1460
Collaborative Group on Hormonal factors in Breast Cancer.- Breast Cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet
1997,350:1047
Clemons M,Gross P Estrogen and de risk of breast cancer. New England J.Med. 2001, 344:276
Bush TL,Whiteman M,Flaws JA. Hormone replacement therapy and breast cancer: a qualitative review. Obstet Gynecol 2001,98:498
Ross WK.Paganini Hill A,Wan PC, et al Effect of hormone replacement therapy on breast cancer:estrogen vsestrogen plus progestin. J.Natl Cancer Inst.2000,92:328
Steimberg KK,Thacker SB,Smith SJ, et al.A metanalysis of the effect of estrogen replacement therapy on the risk of breast cancer JAMA 1991,265:1985
Schaírer C,Lubin J,Troisi R, et el Menopausal estrogen and estrogen/ progestin replacement therapy and breast cancer risk JAMA 2000.283:485
Huang Z,Hankison SEWColditz GA etaIJAMA 1997,278:1407
Millon Women Study Collaborators.Breast cancer and hormone replacement therapy in the millon women study Lancet 2003,362:419
DiSaia PJ,BrewsterWR,Ziogas A et al Breast cancer survival and hormone replacement therapy: a cohort análisis AmJ,Clin Oncol.2000,23:54 1
Bush TL,Whiteman M,Flaws JAHormone replacement therapy and breast cancer: a qualitative review. Obstet Gynecol .2001,98:498
O'Meara ES,Rossing MA,Daling JR et al Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality Journal National Cancer Institute 2001,93:754
Batur P,Blixen CE,Moore HC, et al Menopausal hormone therapy in patients with breast cancer. Cleveland Clinic,Nams, 14th meeting Set.2003,P 49
Women's Health Iniciative- Effects of conjuget equine estrogen in postmenopausal women with hyterectomie. JAMA 2004,291:1701
Sandier RS, Halabi S, Baron JA et al.A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. New Engl J Med 2003,348:1939
Grodstein F,Newcomb PA, Stampfer MJ —Postmenopausal hormone therapy and the risk of colorectal cancer:a review and metanalysis Am.J Med. 1999,106:574
Winawer S,Fletcher R,Rex D et al- Colorectal cancer screening and survillance clinical guide unes and rationale:update based on new evidence. Gastroenterology 2003,124:544
Chlebowsky RT,Wactuwski-Wende J,Ritenbaugh Ch,et al. Estrogen plus progestin and in colorectal cancer in postmenopausal women. N.Engl.J Med 2004,350:991
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2021 Universidad Nacional de Córdoba
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial 4.0 International License.
A geração de trabalhos derivados é permitida, desde que não seja feita para fins comerciais. O trabalho original não pode ser usado para fins comerciais.
Como Citar
